Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Daratumumab in Combination With Chemotherapy in Older Patients With Adverse Risk AML
NCT05749276Phase 1Recruiting
- Sponsor
- CHU de Nantes
- Start
- Feb 2025
- Primary completion
- Aug 2028
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of daratumumab in acute myeloid leukemia (AML), sponsored by CHU de Nantes. Primary endpoint: Dose-Limiting Toxicity at Day 45. Started Feb 2025; status: recruiting.
02
Drugs
daratumumab
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT05749276.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05749276.